Japan's PMDA looks to the future as it balances access and safety
This article was originally published in Scrip
Executive Summary
Since it was set up in April 2004, bringing together drug and medical device regulatory functions then split between various government bodies, the PMDA has not always elicited the kindest of comments from applicants. Frustrations have sometimes been expressed at review times, procedures and difficulties finding slots for consultations. But things have improved markedly over the last few years and the tone of comments one now hears from industry has become much more positive.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.